Therefore, early diagnosis is a crucial factor in treating this type of cancer for which two therapies have been devised so far: one based on BRAF small molecule inhibitors, and the other one on monoclonal antibodies specific for cytotoxic T lymphocyte–associated antigen 4 (CTLA-4). Here, BRAF is linked to cancer.